Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-06-05 | New | $97,655 | $97,655 | Equity Only | 06b | SEC link |
| 2022-10-19 | Amended | $100,000 | $0 | Equity Only | 06b | SEC link |
| 2022-10-18 | New | $100,000 | $100,000 | Equity Only | 06b | SEC link |
| 2020-08-03 | New | $1,052,868 | $1,052,868 | Equity Only | 06b | SEC link |
| 2019-10-24 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
| 2017-11-07 | New | $1,200,000 | $1,200,000 | Equity Only | 06b | SEC link |
| 2016-01-06 | New | $1,100,000 | $1,100,000 | Equity Only | 06b | SEC link |
| 2014-08-29 | New | $980,000 | $980,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Jeff Dunn | Director |
| Jeffrey Dunn | Director |
| Donald Kiepert | Director, Executive |
| Mark Reiley | Promoter |
| B Michael Silber | Executive |
| B. Michael Silber | Director |
| Keith Valentine | Director |